The Lancet · 2016 · 416 citations · 28 references
MedicineNeurologyPharmacologyClinical PharmacologyDementiaNeurodegenerationAlzheimer DiseaseCognitive ImpairmentDementia TreatmentNeurodegenerative DiseasesNeurodegenerative DisordersProtein AggregationAlzheimer Disease Tau PathologyProtein Aggregation InhibitorsTau AggregationTau Protein AggregationTau-targeted Therapy
28
Kelly Posner, Gregory K. Brown, Bárbara Stanley et al. · American Journal of Psychiatry · 2011 · 5K citations
Martin Prince, Anders Wimo, Maëlenn Guerchet et al. · HAL (Le Centre pour la Communication Scientifique Directe) · 2015 · 2.3K citations · Full text
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway, Reisa A. Sperling, Nick C. Fox et al. · New England Journal of Medicine · 2014 · 2K citations · Full text
Medicine, Neurology, Pharmacology +17
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text
Medicine, Neurology, Neuroscience +14